SCHEDULE: RA Capital Boosts SAB Biotherapeutics Stake to 9.9%

RA Capital Management, L.P. and its affiliates have acquired 9.9% of SAB Biotherapeutics' common stock following a private placement and preferred stock conversion.

Summary

• RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (Reporting Persons) filed a Schedule 13D for SAB Biotherapeutics, Inc.
• RA Capital Healthcare Fund, L.P. (the Fund) purchased 171,400 Series B Preferred Shares, 85,700 Release Date Warrants, and 171,400 Enrollment Date Warrants for an aggregate of $29,995,000 in a private placement.
• The Preferred Stock converted into common stock at a conversion price of $1.75 per share after stockholder approval on September 26, 2025.
• Due to a Beneficial Ownership Blocker, the Fund's conversion was capped at 9.99% of outstanding common stock.
• Upon conversion, 44,015 Preferred Stock shares held by the Fund automatically converted to 4,401,500 shares of common stock, representing 9.9% of the outstanding common stock.
• The percentage is based on 44,059,059 shares of common stock outstanding as of September 26, 2025.
• The Reporting Persons acquired the shares for investment purposes and not with an intent to change control.
• The Issuer and the Fund entered into a Letter Agreement for the Issuer to nominate up to two individuals designated by the Fund to the Board of Directors, and to subsequently decrease the Board size by two members to nine persons.
• A resale registration statement for the Registrable Securities was filed on September 2, 2025, and declared effective on September 30, 2025.

Sentiment

Score: 7

Explanation: The filing indicates a substantial investment by a prominent healthcare fund, RA Capital, into SAB Biotherapeutics. The investor's right to nominate board members and the successful conversion of preferred stock are positive signals. The investment is for 'investment purposes' and not to change control, which suggests a supportive, long-term view. The beneficial ownership blocker is a minor limitation but expected in such deals, and the overall execution of the private placement and registration appears to be as planned.

Positives

• A significant investment of $29,995,000 was made by a reputable healthcare investor, RA Capital, into SAB Biotherapeutics.
• RA Capital will have the right to nominate up to two individuals to SAB Biotherapeutics' Board of Directors, potentially bringing valuable expertise and strategic guidance.
• Stockholder approval for the conversion of Preferred Stock and issuance of common stock has been obtained, completing a key step in the investment process.
• A resale registration statement has been declared effective, providing liquidity for the investors regarding their newly acquired common stock.

Negatives

• The Beneficial Ownership Blocker limits RA Capital's immediate conversion of all Preferred Stock, capping their ownership at 9.99% of common stock, which may restrict their immediate influence.
• The Fund disclaims beneficial ownership of the securities it holds for Section 13(d) purposes due to the delegation of voting and investment power to RA Capital, which introduces a layer of complexity in ownership reporting.

Risks

• Reporting Persons may, from time to time, acquire additional equity or debt securities of the Issuer or dispose of Issuer securities they beneficially own, which could impact market dynamics.
• Reporting Persons may engage in communications with persons associated with the Issuer to discuss matters regarding operations, strategic direction, governance, capitalization, and potential business combinations or dispositions, which could lead to strategic shifts.
• The value and exercisability of the Release Date Warrants and Enrollment Date Warrants are dependent on future events, specifically the Phase II Release Date and Phase II Enrollment Date, introducing clinical development risk.

Future Outlook

Reporting Persons acquired the common stock for investment purposes and may, from time to time, acquire additional equity or debt securities or dispose of existing holdings. They may also engage in communications with the Issuer's management and board regarding operations, strategic direction, governance, capitalization, and potential business combinations or dispositions. The Fund has the right to nominate up to two individuals to the Board of Directors.

Industry Context

This filing indicates a significant investment by a specialized healthcare fund (RA Capital) into a biotherapeutics company. Such investments are common in the biotech sector, where capital-intensive R&D requires substantial funding, and strategic investors often seek board representation to guide development and maximize returns. It suggests confidence from a major investor in SAB Biotherapeutics' potential and aligns with a trend of institutional investors taking active stakes in promising life sciences companies.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for increased strategic guidance and oversight from a significant institutional investor on the board. The effective registration statement provides liquidity for the investor, which could impact trading dynamics.
• Management: Will need to collaborate with new board members nominated by RA Capital, potentially influencing strategic direction and operational decisions.
• Company (SAB Biotherapeutics): Received a significant capital infusion of $29,995,000, strengthening its financial position and supporting ongoing operations and development.

Next Steps

• The Fund may designate up to two individuals for nomination to the Issuer's Board of Directors.
• The Issuer will decrease the size of its Board of Directors by two members to nine persons upon the nomination of RA Nominees.
• Reporting Persons may acquire additional equity or debt securities or dispose of existing holdings based on market conditions and the Issuer's prospects.
• Reporting Persons may engage in discussions with the Issuer's management and board regarding strategic matters, governance, and potential business combinations.
• Warrants are exercisable upon receipt of Stockholder Approval until five years from issuance or 30 trading days after notice of Phase II Release Date/Enrollment Date.

Key Dates

Recommendation

The filing indicates a significant strategic investment by RA Capital, a respected healthcare fund, which is generally a positive signal. The capital raise strengthens SAB Biotherapeutics' financial position, and the potential addition of RA Capital nominees to the board could bring valuable expertise and oversight. However, this is primarily an beneficial ownership disclosure and does not contain new operational or clinical data that would warrant a 'buy' or 'strong buy' recommendation without further analysis of the company's fundamentals and pipeline progress. The 'Beneficial Ownership Blocker' and the investor's stated intent to potentially acquire or dispose of shares in the future introduce some uncertainty. Therefore, a 'hold' recommendation is appropriate, suggesting investors maintain their current position while awaiting further operational updates and assessing the impact of RA Capital's involvement.

Keywords

SAB Biotherapeutics, RA Capital Management, Schedule 13D, Common Stock, Preferred Stock, Private Placement, Investment, Beneficial Ownership, Board Nomination, Warrants, Biotechnology, Healthcare Investment